5 Followers on Owler

DTx Pharma

DTx Pharma is a biotechnology company that researches and develops RNA-based therapies for the treatment of rare diseases. Read more

Arthur T. Suckow's photo - Co-Founder & CEO of DTx Pharma

Co-Founder & CEO

Arthur T. Suckow

CEO Approval Rating

92/100

Founded:

2017

Status:

PrivateIndependent Company

DTX PHARMA TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

Locanabio is the top competitor of DTx Pharma. Locanabio was founded in 2016, and its headquarters is in San Diego, California. Like DTx Pharma, Locanabio also operates in the Biotechnology field.

Regulus is seen as one of DTx Pharma's top competitors. Regulus was founded in San Diego, California} in 2007. Like DTx Pharma, Regulus also works within the Biotechnology field. Compared to DTx Pharma, Regulus generates $10M more revenue.

Dicerna is DTx Pharma's #3 rival. Dicerna's headquarters is in Lexington, Massachusetts, and was founded in 2006. Like DTx Pharma, Dicerna also operates in the Biotechnology sector. Dicerna generates 3,557% of DTx Pharma's revenue.

Weigh-in!

Help the Owler community know more

Growth Score - 1/1

Is $5M a good estimate for DTx Pharma's revenue?

DTx Pharma Acquisitions

No recent acquisitions found related to DTx Pharma

DTx Pharma Funding History

Since DTx Pharma was founded in 2017, it has participated in 5 rounds of funding. In total DTx Pharma has raised $123.8M. DTx Pharma's last funding round was on Feb 2021 for a total of $100.0M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

Series B
Feb 2021
$100M

RA Capital Management

Debt
Jun 2020
$200K
-
Series A
Jan 2020
$10.6M
Equity
Apr 2019
$12M
-
Unattributed
Aug 2017
$1M
-

Since DTx Pharma was founded in 2017, it has participated in 5 rounds of funding. In total DTx Pharma has raised $123.8M. DTx Pharma's last funding round was on Feb 2021 for a total of $100.0M

DTx Pharma Investments

No recent investments found related to DTx Pharma

DTx Pharma News

March 19, 2021Venture Capital Journal

DTx Pharma picks up $100m Series B

DTx Pharma Inc, a biotechnology company, has raised $100 million in Series B financing.... See more »
March 17, 2021San Diego Business Journal

DTx Pharma Raises $100 Million Round

BIOTECH: Funding to Be Used to Accelerate Efforts, Advance Pipeline... See more »
March 5, 2021FinSMEs

DTx Pharma Closes $100M Series B Financing

DTx Pharma, Inc., a San Diego, CA-based...... See more »
May 21, 2020Area Development Online

DTx Pharma Expands Research & Operations at New Facility in San Diego, California

DTx Pharma Inc., a privately-held biotechnology company creating novel RNA-based therapeutics to trea... See more »
January 10, 2020BioPortfolio

DTx Pharma Raises $10.6M to Advance New Way to Deliver RNA Drugs

RNA medicines can treat some diseases by hitting targets otherwise considered undruggable by small mo... See more »
January 10, 2020firstwordpharma

DTx Pharma Completes $10.6M Series A Financing

DTx Pharma announced today the final closing of a Series A financing totaling $10.6 million dollars. ... See more »
May 12, 2019San Diego Business Journal

DTx Pharma Raises $3 Million, Hopes Its Trojan Horse Is a Winner

DTx Pharma, a Torrey Pines startup developing a way to make more effective RNA treatments, recently r... See more »

DTx Pharma Press Releases

September 28, 2020PR Newswire

DTx Pharma to Present at the Chardan Virtual 4th Annual Genetic Medicines Event

SAN DIEGO, Sept. 28, 2020 /PRNewswire/ -- DTx Pharma, Inc. (DTx), a privately-held biotechnology comp... See more »
September 22, 2020PR Newswire

DTx Pharma Receives New Funding Grant to Advance RNA-based Therapeutic Programs for Charcot-Marie Tooth (CMT)

SAN DIEGO, Sept. 22, 2020 /PRNewswire/ -- DTx Pharma, Inc. (DTx), a privately-held biotechnology comp... See more »
September 16, 2020PR Newswire

DTx Pharma Announces Presentations at Several Upcoming Virtual Medical Meetings

SAN DIEGO, Sept. 16, 2020 /PRNewswire/ -- DTx Pharma, Inc. (DTx), a privately-held biotechnology comp... See more »
May 13, 2020PR Newswire

DTx Pharma Receives Prestigious Funding Award to Support Research in Neurodegenerative Diseases of the CNS

SAN DIEGO, May 13, 2020 /PRNewswire/ -- DTx Pharma, Inc. (DTx), a privately-held biotechnology compan... See more »

Social Media

DTx Pharma Headquarters

10655 Sorrento Valley Road Suite 100

San Diego, California92121

858-792-3601

Driving Directions »

Trending Companies

DTx Pharma Summary

ABOUT

Overview

DTx Pharma is a biotechnology company that researches and develops RNA-based therapies for the treatment of rare diseases. DTx Pharma was founded in 2017. DTx Pharma's headquarters is located in San Diego, California, USA 92121. It has raised 123.8M i...

CEO

DTx Pharma's Co-Founder & CEO, Arthur T. Suckow, currently has an approval rating of 92%. DTx Pharma's primary competitors are Locanabio, Regulus & Dicerna.

Frequently Asked Questions about DTx Pharma

  1. When was DTx Pharma founded?

    DTx Pharma was founded in 2017
  2. Who is DTx Pharma's CEO?

    DTx Pharma's CEO is Arthur T. Suckow
  3. How much revenue does DTx Pharma generate?

    DTx Pharma generates $5M in revenue
  4. How much funding does DTx Pharma have?

    DTx Pharma has historically raised $123.8M in funding
  1. Where is DTx Pharma's headquarters?

    DTx Pharma's headquarters is in San Diego California, USA
  2. How many employees does DTx Pharma have?

    DTx Pharma has 30 employees
  3. What sector does DTx Pharma operate in?

    DTx Pharma is in Biotechnology, Pharmaceuticals
  4. Who are DTx Pharma's competitors?

    DTx Pharma's top competitors are Locanabio, Regulus, Dicerna